```markdown
---
application_number: 206185Orig1s000
drug_name: Xelpros
dosage_form: latanoprost ophthalmic emulsion, 0.005%
sponsor: Sun Pharma Advanced Research Company Limited
c/o: Ora, Inc.
submission_type: NDA (505(b)(2))
initial_submission_date: 2014-01-31
fda_action_dates:
  - 2014-11-24
  - 2015-07-30
  - 2016-12-19
facility_site:
  name: Sun Pharmaceutical Industries, Ltd.
  locations:
    - Halol, India
regulatory_status: Not approved; Complete Response Letters issued
contact_persons:
  - name: Judit Milstein
    title: Chief, Project Management Staff
    phone: 301-796-0763
  - name: Diana Willard
    title: Chief, Project Management Staff
    phone: 301-796-1600
fda_signatory: Renata Albrecht, M.D.
fda_office: Division of Transplant and Ophthalmology Products
---

## Critical Data

| Field                       | Details                                                           |
|----------------------------|-------------------------------------------------------------------|
| Application Number         | 206185Orig1s000                                                   |
| Drug Name                  | Xelpros                                                           |
| Dosage Form                | latanoprost ophthalmic emulsion, 0.005%                           |
| Sponsor                    | Sun Pharma Advanced Research Company Limited                      |
| Submission Type            | NDA under 505(b)(2)                                               |
| Initial Submission Date    | January 31, 2014                                                  |
| Facility Inspected         | Sun Pharmaceutical Industries, Ltd. - Halol, India               |
| FDA Action Dates           | November 24, 2014; July 30, 2015; December 19, 2016               |
| Current Status             | Not approved—Complete Response Letters issued                    |
| Primary FDA Contact Names  | Judit Milstein, Diana Willard                                     |
| Signatory                  | Renata Albrecht, M.D.                                             |
| Key Review Issues          | Product quality, facility deficiencies, labeling, proprietary name, safety updates |
| Required Safety Update Ref | 21 CFR 314.50(d)(5)(vi)(b)                                        |

---

# CENTER FOR DRUG EVALUATION AND RESEARCH  
## APPLICATION NUMBER: 206185Orig1s000  
## COMPLETE RESPONSE LETTERS

---

## Letter Dated December 19, 2016

**To:**  
Sun Pharma Advanced Research Company Limited  
c/o Ora, Inc.  
Attention: Mr. Aron Shapiro  
Vice President  
300 Brickstone Square  
Andover, MA 01810

**Subject:** Xelpros (latanoprost ophthalmic emulsion), 0.005%

Please refer to your New Drug Application (NDA) dated and received January 31, 2014, pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for Xelpros.

We acknowledge receipt of your amendment dated July 28, 2016, which constituted a complete response to our July 30, 2015 action letter.

We have completed our review and determined that we cannot approve the application in its present form. Below are the issues identified:

### Product Quality / Facilities Inspection

A recent inspection of Sun Pharmaceutical Industries, Ltd., manufacturing facility revealed deficiencies. Satisfactory resolution is required prior to approval.

### Labels and Labeling

We acknowledge the submission of labeling materials (carton, container labels, prescribing info) on July 28, 2016. We reserve comment until the application is otherwise adequate.

### Proprietary Name

Refer to correspondence dated October 3, 2016. The name "Xelpros" is acceptable pending approval. Please resubmit with your response to application deficiencies.

### Safety Update

When responding to the deficiencies, include a safety update per 21 CFR 314.50(d)(5)(vi)(b), covering:

1. Significant changes/findings in the safety profile  
2. Discontinuations and adverse event section updates:
   - Present new safety data using the original format
   - Tabulate new with original NDA data
   - Tables comparing old vs. new frequencies
   - Separate tables for other indications  
3. Retabulate reasons for trial discontinuation  
4. Case report forms and narrative summaries for:
   - Deaths  
   - Non-completion due to adverse events  
   - Serious adverse events  
5. Changes in common but less serious adverse events  
6. Updated exposure information (subjects, person-time)  
7. Summary of global safety experience and usage estimates  
8. English translations of approved foreign labeling, if not submitted previously  

### Other

Within one year of this letter, actions must be taken per 21 CFR 314.110. Failure to act may result in withdrawal per 21 CFR 314.65.

A resubmission:
- Must clearly state "RESUBMISSION"
- Fully address all deficiencies
- Partial responses will not be processed

Meeting requests should follow the FDA draft guidance “Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products,” (March 2015):  
[http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm437431.pdf](http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm437431.pdf)

The drug cannot be legally marketed until written approval is issued.

**Contact:**  
Judit Milstein, Chief, Project Management Staff  
Phone: 301-796-0763

**Signed:**  
Renata Albrecht, MD  
Director  
Division of Transplant and Ophthalmology Products  
Office of Antimicrobial Products  
Center for Drug Evaluation and Research

---

## Letter Dated July 30, 2015

**To:**  
Sun Pharma Advanced Research Company Limited  
c/o Ora, Inc.  
Attention: Mr. Aron Shapiro  
Vice President  
300 Brickstone Square  
Andover, MA 01810

**Subject:** Xelpros (latanoprost ophthalmic emulsion), 0.005%

We acknowledge receipt of your amendments dated:
- November 26, 2014  
- April 9, 2015  
- May 12, 2015

Your April 9, 2015 submission constituted a complete response to the November 24, 2014 action letter.

### Prescribing Information

1. Submit revised labeling from this correspondence (based on April 9, 2015 submission). Carton/container labels are acceptable—resubmit them.

### Facility Inspections

2. Deficiencies found at Halol, India manufacturing facility must be satisfactorily resolved.

### Proprietary Name

3. "Xelpros" deemed acceptable per July 16, 2015 letter. Resubmit with response to deficiencies.

### Safety Update

Include update per 21 CFR 314.50(d)(5)(vi)(b), as detailed above (see December 19, 2016 letter for full list of safety update requirements).

### Other

See section in previous letter for process under 21 CFR 314.110 and meeting requests per May 2009 guidance:  
[http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM153222.pdf](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM153222.pdf)

**Contact:**  
Ms. Diana Willard, Chief, Project Management Staff  
Phone: 301-796-1600

**Signed:**  
Renata Albrecht, M.D.

Enclosure: Labeling

---

## Letter Dated November 24, 2014

**To:**  
Sun Pharma Advanced Research Company Limited  
c/o Ora, Inc.  
Attention: Mr. Aron Shapiro  
Vice President  
300 Brickstone Square  
Andover, MA 01810

**Subject:** Xelpros (latanoprost ophthalmic emulsion), 0.005%

We acknowledge receipt of amendments dated:
- February 7, 2014  
- February 21, 2014  
- March 5, 2014  
- March 14, 2014  
- March 27, 2014  
- April 11, 2014  
- April 30, 2014  
- May 23, 2014  
- June 6, 2014  
- June 27, 2014  
- July 9, 2014  
- July 25, 2014  
- September 30, 2014  
- October 21, 2014  
- October 30, 2014

### Product Quality

1. Update the name throughout NDA to indicate correct dosage form: "latanoprost ophthalmic emulsion". Submit "Erratum" page.  
2. Proposed acceptance limits for certain impurities can be tightened. Revise to appropriate release and stability limits.

### Prescribing Information

3. Ensure prescribing information conforms to 21 CFR 201.56(a), (d), and 201.57. Use SRPI checklist. Submit in SPL format with:
   - Marked-up copy  
   - Clean Microsoft Word version  
   - Annotations for any proposed changes

### Carton and Container Labeling

4. Labels submitted on July 9, 2014 include the phrase "(b)(4)". Replace this with "For Topical Use in the Eye."

### Facility Inspections

5. Deficiencies at Halol, India manufacturing facility must be resolved satisfactorily.

### Proprietary Name

Refer to May 19, 2014 correspondence. "Xelpros" acceptable pending application approval. Resubmit with your response.

### Safety Update

Include safety update per 21 CFR 314.50(d)(5)(vi)(b), as detailed in prior letters.

### Other

Respond within one year or request extension. Resubmission must fully address all deficiencies. Partial responses will not start a new review clock.

Meeting requests per FDA May 2009 guidance:  
[http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM153222.pdf](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM153222.pdf)

**Contact:**  
Ms. Diana Willard, Chief, Project Management Staff  
Phone: 301-796-1600

**Signed:**  
Renata Albrecht, M.D.

Enclosure: Labeling
```